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ABSTRACT 
Alzheimer’s disease (AD) is a neurogenetic condition that affects the processes via which the brain functions. 
Major observable hallmarks of AD are accumulated clusters of proteins in the brain. These clusters, termed 
neurofibrillary tangles (NFT), resemble pairs of threads wound around each other in a helix fashion 
accumulating within neurons. These tangles consist of a protein called Tau, which binds to tubulin, thus 
forming microtubules. Unlike NFTs, deposits of amyloid precursor protein (β-APP) gather in the spaces 
between nerve cells. The nearby neurons often look swollen and deformed, and the clusters of protein are 
usually accompanied by reactive inflammatory cells, microglia, which are part of the brain’s immune system 
responsible for degrading and removing damaged neurons or plaques. Since phosphorylation/dephosphorylation 
mechanisms are crucial in the regulation of Tau and β-APP, a superfamily of mitogen-activated protein kinases 
(MAPKs) has recently emerged as key regulators of the formation of plagues, eventually leading to dementia 
and AD. The complex molecular interactions between MAPKs and proteins (plagues) associated with the 
evolution of AD form a cornerstone in the knowledge of a still burgeoning field of neurodegenerative diseases 
and ageing. This review overviews current understanding of the molecular pathways related to MAPKs and 
their role in the development of AD and, possibly, dementia. MAPKs, therefore, may constitute a neurogenetic, 
therapeutic target for the diagnosis and evolution of a preventative medical strategy for early detection, and 
likely treatment, of Alzheimer’s. 
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1. Introduction 
 
The syndrome of dementia, which represents a 
progressive deterioration in intellectual abilities, can 
be so severe to an extent it may interfere with the 
person’s usual social and occupational functioning 
(Burnham, 1988; Floyd, 1999; Harper and LoGrasso, 
2001; Peel, 2004; Samanta et al., 2006; Wurtman, 
1985). An estimated 5-10 % of the US adult 
population (ages 65 and older) is affected by a 
dementing disorder, and the incidence doubles almost 
every 5 years among people falling within this age 
group (Drachman, 2006; Erickson, 1991; Sellcoe, 
1991; Runden et al., 1998). 
 
Alzheimer's disease (AD) is the most common form of 
dementia, especially in the US; it and related 
dementias affect at least 2 million, and possibly as 
many as 4 million, residents. Despite its prevalence, 
dementia often goes unrecognized or is misdiagnosed 
in its early stages (Beardsley, 1993; Beardsley, 1995; 
Jellinger, 2006; Zhu et al., 2001a). Some disorders 
that result in dementia are ‘reversible’ or ‘potentially 
reversible,’ which means that they can be treated 
effectively to restore normal or nearly normal 
intellectual function (Giannakopoulos, et al., 2007; St 
George-Hyslop, 2000).  
 
Among the most frequent reversible causes of 
dementia are depressions, alcohol abuse and drug 
toxicity (Suram et al., 2006). In elderly persons, drug 
use — particularly drug interactions caused by ‘poly-
pharmacy’ (simultaneous use of multiple drugs) — is 
a common cause of cognitive decline (Uhlhaas and 
Singer, 2006). Depression also is an under-diagnosed 
condition in this population (Erickson, 1991). 
However, the majority of dementias, including AD, 
are considered non-reversible. Even for these 
conditions, correct diagnosis of the problem in its 
early stages can be beneficial (Martindale, 2002). In 
addition, many of the non-reversible dementias 
include symptoms such as incontinence, wandering 
and depression that can be treated effectively (Dickey 
and Petrucelli, 2006; Wurtman, 1985). 
 
The underlying factors contributing to the evolution 
and perpetuation of AD remain largely obscure 
(Martindale, 2002; St. George-Hyslop, 2000). 
Biomedical researchers have devised psychological 
screening tests to try to identify people in the early 
stages of AD. Apart from memory loss, there are nine 
other warning signs — among them difficulty 
performing familiar tasks, problems with language, 
such as remembering words, disorientation in time 
and space, and changes in personality. Susceptible 
people appear to have a greater sensitivity to the drug 
tropicamide, which is ordinarily used to dilate the 
pupils in a routine eye exam (Martindale, 2002; 
Wurtman, 1985). But for the most part, diagnosis has 
been a process of elimination. Microscopic views, for 
instance, have revealed a loss of nerve cells in certain 
regions of the brain, such as the hippocampus, a 
center for memory, and the cerebral cortex, which is 
involved in reasoning, memory, language and other 
important thought processes (Morgan, 2006; St 
George-Hyslop, 2000).  
 
The other more directly observable hallmarks of AD 
are clusters of proteins that accumulate in the brain. 
These accumulations usually occur in two forms: 
those found inside nerve cells and those found 
between cells. The clusters in the interior are called 
neurofibrillary tangles (NFTs) and they resemble pairs 
of threads wound around each other in a form of a 
helix. Biochemical analyses showed that these tangles 
consist of a protein called Tau (Anderton et al., 2001; 
Dickey and Petrucelli, 2006). Tau is significant 
because it binds to a protein named tubulin, which in 
turn forms structures known as microtubules 
(microtubules are crucially important in the structural 
framework of living cells). Like the girders and pillars 
of buildings, they run through cells, thereby imparting 
support and shape. Microtubules also provide routes 
along which nutrients, other molecules and cellular 
components such as vesicles and mitochondria move 
through cells (Johnson, 2006; Martindale, 2002; St 
George-Hyslop, 2000).  
 
Unlike NFTs, deposits of amyloid protein gather in 
the spaces between nerve cells. The nearby neurons 
often look swollen and deformed, and the clusters of 
protein ⎯ sometimes called senile or amyloid plaques 
⎯ are usually accompanied by reactive inflammatory 
cells called microglia, which are part of the brain’s 
natural immune system that help degrade and remove 
damaged neurons or perhaps the plaques themselves 
(Haddad 2002e; Martindale, 2002). It is unclear, 
however, whether the neurons in or near these plaques 
function normally, because the density of plaques is 
only weakly correlated with the severity of dementia. 
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Further, such plaques are present in most elderly 
people. Nevertheless, their extensive presence in the 
hippocampus and the cerebral cortex is specific to AD 
and they appear long before NFTs do (Higuchi et al., 
2005).  
 
Intensive efforts to isolate the ingredients of these 
plaques culminated with the discovery that a principal 
component was a peptide made up of 40-42 amino 
acids (St George-Hyslop, 2000). The sequencing of 
the gene for the longer protein from which this 
peptide originates quickly followed this identification 
of what is now termed the β-amyloid peptide: the β-
amyloid precursor protein (β-APP). Although the 
precise biological role of normal β-APP molecules 
remains obscure, it is currently known that many 
kinds of cells and tissues produce β-APP and that it 
can be between 695 and 770 amino acids long 
(Martindale, 2002). The protein runs through the outer 
cell membrane, with a short piece jutting into the cell 
and a longer piece sticking into the extracellular 
space. The β-amyloid peptide, for its part, is snipped 
out of the section of β-APP that spans the cell 
membrane. β-APP is cut in one of two ways: in one 
process, the protein is first cleaved by an enzyme 
called α-secretase; it is then cut by another putative 
enzyme, γ-secretase. Together these cuts produce a 
harmless peptide fragment called p3 (St George-
Hyslop, 2000). The second way in which β-APP is 
cleaved is another two-step process, one that is not 
always so harmless. First, an enzyme called β-
secretase clips the protein; one of the resulting pieces, 
called C99-β-APP fragment, is then snipped by γ-
secretase and the β-amyloid peptide is born (Dickey 
and Petrucelli, 2006).  
 
At the molecular level, the biochemical, molecular, 
genetic, epidemiological and clinical discoveries have 
significantly advanced our understanding of the 
mechanisms underlying the evolution of AD and 
made it increasingly likely that, in the years to come, 
useful therapeutic treatments will be proposed. Some 
of these will probably come from the recent insights 
into the mis-processing or phosphorylation of Tau, a 
key mechanism in the regulation of Alzheimer’s 
(Blennow et al., 2006; St George-Hyslop, 2000). 
Indeed, the insights into β-APP and β-amyloid peptide 
are already fueling treatment research. For instance, 
some investigators are designing compounds that will 
block the ability of either β- or γ-secretase enzymes to 
cut β-APP, thus preventing the creation of the 
damaging β-amyloid peptide. Others are seeking to 
alleviate the peptide’s effects once it has been created. 
Clinical trials are under way to investigate whether 
antioxidants, such as vitamin E, or non-steroidal anti-
inflammatory drugs (NSAIDS), such as ibuprofen, 
could alleviate some of the toxic effects of β-amyloid 
(Kanaan et al., 1997; Blennow et al., 2006; St George-
Hyslop, 2000).  
 
Since phosphorylation/dephosphorylation mechanisms 
are crucial in the regulation of Tau and β-APP 
(Hwang et al., 2004; Iqbal and Grundke-Iqbal, 2006), 
a superfamily of mitogen-activated protein kinases 
(MAPKs) has recently emerged as key regulators of 
the formation of plagues, eventually leading to 
dementia and AD (Wang et al., 2004) (Fig. 1). To this 
end, this review will focus on the mechanisms 
mediated by MAPKs, which may modulate AD-
related proteins and their functions and thereby can 
potentially determine the development of NFTs and, 
perhaps, the evolution of AD. 
 
2. MAPK signaling modules and pathways: A 
network overview 
 
2.1. MAPK signaling pathways as viewed through 
their identification and bifurcations 
Signal transduction at the cellular level refers to the 
movement of signals (messages) from outside 
(extracellular) the cell to inside (intracellular) 
(Chattopadhyay and Brown, 2000; Dhanasekaran and 
Dermott, 1996; Guha and Mackman, 2001; Haddad, 
2001; Haddad, 2002a; Haddad et al., 2002; Haddad et 
al., 2003; Holmes-McNary, 2002; Inui et al., 2001; 
Kim et al., 1999; Levin, 2002; Lowes et al., 2002; 
Meriin et al., 1998; Nakamura et al., 1996; 1998; 
2002; Plyte et al., 2000; Sontag, 2001). The 
movement of signals can be simple, like that 
associated with receptor molecules of the 
acetylcholine class receptors that constitute channels 
which, upon ligand interaction, allow signals to be 
passed in the form of small ion movement, either into 
or out of the cell (Chattopadhyay and Brown, 2000; 
Dhanasekaran and Dermott, 1996; Guha and 
Mackman, 2001; Haddad, 2002b; Haddad et al., 2003; 
Pursiheimo et al., 2002; Sontag, 2001).  
 
These ion movements result in changes in the 
electrical potential of the cells that, in turn, propagates 
the signal spatially along the cell. More complex 
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signal transduction, furthermore, involves the 
coupling of ligand-receptor interactions to many 
intracellular events. These events include 
phosphorylations by tyrosine kinases and/or 
serine/threonine kinases (Haddad, 2001; Haddad, 
2002c; Haddad et al., 2003; Holmes-McNary, 2002; 
Levin, 2002; Lowes et al., 2002). The phosphorylation 
of proteins may change enzyme activities and protein 
conformations. The eventual outcome is an alteration 
in cellular activity and changes in the programming of 
genes expressed within the responding cells (Haddad, 
2005). Phosphorylation and dephosphorylation 
mechanisms schematically involved in the regulation 
of gene transcription are shown in Fig. 1. 
 
 
Figure 1: A hypothetical model of gene regulation where the switch on/off mediates a series of 
phosphorylation/dephosphorylation steps regulated by kinases and phosphatases, respectively. This 
sequential propagation of signals occurs in response to a stimulus over a pre-specified period of time. 
 
 
MAPKs were identified by virtue of their activation in 
response to growth factor stimulation of cells in 
culture, hence the name mitogen-activated protein 
kinases (Fig. 2) (Avruch et al., 2001; Cano and 
Mahadevan, 1995; Chakraborty, 2001; Haddad, 
2002a; Haddad et al., 2003; Kennedy et al., 1999; Lee 
et al., 2000; Mordret, 1993; Pierce et al., 2001). MAP 
kinases are also called extracellular receptor kinases 
(ERKs) for extracellular-signal regulated kinases. On 
the basis of in vitro substrates, the MAP kinases have 
been variously called microtubule associated protein-2 
kinase (MAP-2 kinase), myelin basic protein kinase 
(MBP kinase), ribosomal S6 protein kinase (RSK-
kinase; i.e., a kinase that phosphorylates a kinase) and 
epidermal growth factor (EGF) receptor threonine 
kinase (ERT kinase) (Avruch et al., 2001; Bardwell, 
2006; Cano and Mahadevan, 1995; Chakraborty, 
2001; Haddad, 2001; Haddad et al., 2003; Kennedy et 
al., 1999; Lee et al., 2000; Pierce et al., 2001). All of 
these proteins have similar biochemical properties, 
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immuno-cross-reactivities, amino acid sequence and ability to in vitro phosphorylate similar substrates.  
 
Figure 2: The modules and various components of the MAPK signaling pathways. The cellular 
response to growth factors, inflammatory cytokines and other mitogens is often mediated by 
receptors that either are G-protein-linked or are intrinsic protein tyrosine kinases. The binding of the 
ligand to receptor tyrosine kinases induces dimerization and auto-phosphorylation (activation) of the 
kinase. The activated tyrosine kinase binds to and phosphorylates an adaptor protein, such as Grb2, 
that, in turn, activates a guanine nucleotide exchange factor, such as mSOS, that, in turn, activates a 
small GTP-binding protein, such as Ras or Rac. The GTP-binding proteins then transmit the signal to 
one of several cascades of protein Ser/Thr kinases that utilize the sequential phosphorylation of 
kinases to transmit and amplify the signal. These kinase cascades are collectively known as mitogen-
activated protein kinase (MAPK) signaling cascades. The best studied of these kinase cascades is 
the MAPKERK (MAPKp44/p42) signaling cascade. Downstream targets of MAPKERK include p90rsk (p90 
risobomal S6 protein kinase) and the Elk-1 and Stat3 transcription factors. The Jun kinase 
(MAPKJNK/SAPK) and MAPKp38 kinase (HOG) pathways are stress-activated MAP kinase cascades. 
The MAPKJNK cascade is activated by inflammatory cytokines as well as by heat shock and UV 
irradiation. Downstream targets of MAPKJNK include the transcription factors c-Jun and ATF-2. The 
MAPKp38 pathway is activated by bacterial endotoxins, inflammatory cytokines and osmotic stress. 
Downstream targets of MAPKp38 include the transcription factors ATF-2, Max and CREB. MAPKp38 is 
also involved in the phosphorylation and activation of heat shock proteins.  
 
Maximal MAP kinase activity requires that both 
tyrosine and threonine residues are phosphorylated. 
This indicates that MAP kinases act as switch kinase 
that transmits information of increased intracellular 
tyrosine phosphorylation to that of serine/threonine 
phosphorylation (Guan, 1994; Haddad 2001; Haddad 
2002d; Ono and Han, 2000; Sugden and Clerk, 1997). 
Although MAP kinase activation was first observed in 
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response to activation of EGF, platelet-derived growth 
factor (PDGF), nerve growth factor (NGF) and insulin 
and insulin-like receptors, other cellular stimuli such 
as T-cell activation (which signals through the Lck 
tyrosine kinase), phorbol esters (that function through 
activation of protein kinase C (PKC)), thrombin, 
bombesin and bradykinin (that function through G-
proteins), as well as N-methyl-D-aspartate (NMDA) 
receptor activation and electrical stimulation rapidly 
induce tyrosine phosphorylation of MAP kinases 
(Avruch et al., 2001; Cano and Mahadevan, 1995; 
Chakraborty, 2001; Guan, 1994; Kennedy et al., 1999; 
Lee et al., 2000; Mordet, 1993; Ono and Han, 2000; 
Pierce et al., 2001; Sugden and Clerk, 1997).  
 
MAP kinases are, however, not the direct substrates 
for receptor tyrosine kinases (RTKs) or receptor-
associated tyrosine kinases but are in fact activated by 
an additional class of kinases termed MAP kinase 
kinases (MAPK kinases) and MAPK kinase kinases 
(MAPKK kinases). One of the MAPK kinases has 
been identified as the proto-oncogenic 
serine/threonine kinase, Raf (Bendinelli et al., 1995; 
Cazaubon et al., 1994; Chen et al., 1996; Cobb et al., 
1994; English and Cobb, 2002; Errede et al., 1995; 
Haddad 2001; Hagemann and Blank, 2001; Kolch, 
2000; Lee and McCubrey, 2002; Liebmann, 2001; 
Marshall, 1995; McCubrey et al., 2000; Morrison, 
1995; Oppenheimer et al., 2000; Schlesinger et al., 
1998; Sebolt-Leopold, 2000; Tibbles and Woodgett, 
1999; Weinstein- Zhu et al., 2001b).  
 
Ultimate targets of the MAP kinases are several 
transcriptional regulators such as serum response 
factor (SRF) and the proto-oncogenes Fos, Myc and 
Jun, as well as members of the steroid/thyroid 
hormone receptor super family of proteins. The 
simplified core of a MAPK cascade consists of three 
protein kinases: A MAP kinase kinase kinase 
(MAPKKK), a MAP kinase kinase (MAPKK) and 
MAP kinase (MAPK); these kinases phosphorylate 
each other in sequence. When activated, MAPKKK 
phosphorylates the MAPKK at one or two 
phosphorylation sites, bringing activation of the 
MAPKK module. MAPKKs are dual-specificity 
protein kinases that phosphorylate the MAPK at two 
phosphorylation sites (almost always a threonine and 
a tyrosine residue), bringing about activation of the 
MAPK. The active MAPK can then phosphorylate a 
variety of target proteins throughout the cytoplasm 
and nucleus (Bardwell, 2006).  
On the internal regulatory mechanisms, each of the 
kinases in the MAPK cascade is opposed by one or 
more phospho-protein phosphatases. Thus, for an 
active MAPKK to activate a MAPK, for example, the 
rate of MAPK phosphorylation must exceed the rate 
of MAPK de-phosphorylation. The activities of these 
phosphatases are high enough to make the output of a 
MAPK cascade depend upon the continual presence 
of a stimulus feeding into the cascade; if this 
particular stimulus is withdrawn, for instance, the 
downstream kinases become inactivated within a very 
short lapse of time (Figure 2) (Avruch et al., 2001; 
Cano and Mahadevan, 1995; Chakraborty, 2001; 
Cullen and Lockyer, 2002; English and Cobb, 2002; 
Haddad et al., 2003; Kennedy et al., 1999; Lee and 
McCubrey, 2002; Lee et al., 2000; Mordret, 1993; 
Pierce et al., 2001). 
 
The best-characterized vertebrate MAPKs fall into 
three major subgroups (Figure 2). The first subgroup 
includes the founding members of the MAPK family, 
extracellular signal-regulated kinase-1 (ERK1; 
MAPKERK1/p44) and ERK2 (MAPKERK2/p42), and their 
closest relatives (Bardwell, 2006; Belcheva and 
Coscia, 2002; Daulhac et al., 1997; Denhardt, 1996; 
Frye, 1992; Howe et al., 2002; Peyssonnaux and 
Eychene, 2001; Zhang et al., 2000). This subgroup is 
often referred to as ERKs, although some ERK 
proteins are not in fact members of this subgroup 
family.  
 
The second subgroup is the Jun N-terminal kinases 
(JNKs), so called because they can activate the Jun 
transcription factor by phosphorylating two residues 
near its N-terminus (Barr and Bogoyevitch, 2001; 
Davis, 2000; Dickens et al., 1997; Dong et al., 2001; 
Fleming et al., 2000; Harper and LoGrasso, 2001; Ip 
and Davis, 1998; Leppa and Bohmann, 1999; Mielke 
and Herdegen, 2000; Noselli, 1998; Noselli and 
Agnes, 1999; Okazawa and Estus, 2002; Rincon et al., 
2000; Weston and Davis, 2002; Yao et al., 1997).  
 
The third subgroup is the p38 MAPKs, so named 
because of the molecular weight (38 kDa) of the first 
representative of the subgroup to be discovered 
(Bulavin et al., 2002; English et al., 1999; Haddad, 
2001; Ichijo, 1999; Lee and Young, 1996; Lopez-
Ilasaca, 1998; Obata et al., 2000; Rincon, 2001). 
Members of both the MAPKJNK and MAPKp38 
pathways are also classified as stress-activated protein 
kinases (SAPKs), because they are activated in 
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response to osmotic shock, UV irradiation, 
inflammatory cytokines and other stressful conditions 
(Haddad et al., 2003).  
 
In all three subgroups, a large number of MAKKKs 
feed into the activation of a smaller number of 
MAPKKs and MAPKs. The diversity of the 
MAPKKKs thus allows a wide variety of upstream 
receptors to couple to MAPK cascades (Fig. 2) 
(Haddad, 2002a; Haddad, 2002f; Haddad and Land, 
2002; Lewis et al., 1998; Marshall, 1994; Pearson et 
al., 2001). MAPKs and their corresponding substrates 
are given in Table 1. 
 
 
Table 1: MAPKs and downstream transcription factors and substrates. 
__________________________________________________________________________________________ 
 
KINASE    SUBSTRATES 
 
MAPKERK    Elk-1; SAP-1; Mnk-1/2; MAPKAP-K1/p90Rsk; MSK-1 
MAPKJNK/SAPK   c-Jun; ATF-2; Elk-1 
MAPKp38 ATF-2; Elk-1; SAP-1; CHOP; MEF2C; MAPKAP-K2/K3; Mnk-1/2; MSK-1; PRAK 
 
MAPKAP-K1/p90Rsk  c-Fos; SRF 
 
MSK-1  CREB; Histone H3 and HMG-14 
__________________________________________________________________________________________ 
 
ATF, Activating transcription factor; CHOP, C/EBP homologous protein; CREB, cAMP response element 
binding protein; HMG-14, High mobility group-14; MAPKERK, mitogen-activated protein kinase/extracellular 
signal-regulated kinase; MAPKAP-K, MAPK-activated protein kinase; MEF2C, Myocyte enhancer factor 2C; 
Mnk, MAPK interacting protein kinase; MSK, Mitogen- and stress-activated protein kinase; PRAK, p38-
related/activated protein kinase; Rsk, Ribosomal S6 kinase; SAP-1, SRE accessory protein-1; SRF, Serum 
response factor. 
__________________________________________________________________________________________     
 
 
2.2. MAPK signaling as viewed through receptor and 
non-receptor coupled cofactors 
The MAPKs are a grouping of closely related families 
of Ser/Thr kinases involved in regulating growth, 
differentiation, and cellular responses to stress or 
inflammatory cytokines (Haddad and Fahlman, 2002; 
Haddad et al., 2003). Whereas the MAPKERK pathway 
essentially regulates growth, proliferation and 
differentiation signals, the MAPKJNK/SAPK and 
MAPKp38 pathways regulate cell responses to 
environmental stress.  
 
The MAPKs link signals generated at the cell surface 
to transcription factors via a cascade of 
phosphorylation events basically initiated at the level 
of the membrane by protein tyrosine kinases (PTKs), 
of which two classes exist, the receptor PTKs and 
non-receptor PTKs. Among the PTKs is the Src 
family of non-receptor PTKs composed of at least 
nine members. Most are restricted to defined cellular 
lines, but three (Src, Fyn, Yes) are ubiquitously 
expressed (Courtneidge et al., 1993; Haddad, 2002d; 
Haddad et al., 2003). Like their receptor PTK 
counterparts, the Srcs are at the upper end of the 
MAPK cascade and serve as initiators for the 
transduction of signals generated by receptors at the 
cell surface (Akhand et a., 2002; Pawson, 1994; 
Parsons and Parsons, 1997).  
 
The Ras G-proteins mediate the mitogen-induced 
activation of MAP kinases by activating Raf, a family 
of serine/threonine kinases (Hindley and Kolch, 
2002). The MEK1 and MEK2 are the dominant Raf 
effector proteins, although other Raf substrates have 
been identified (Pearson et al., 2000). Deactivation of 
the MAP kinases is an important regulatory feature of 
the cascade. This is accomplished by phosphatases 
such as MKP-1/2 PAC-1 that dephosphorylate 
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MAPKERK in the nucleus or MPK-3, which 
dephosphorylate cytosolic MAPKERK (Haneda et al., 
1999). The MAP kinases therefore are a convergence 
point for a wide variety of extracellular signals. 
MAPK circuits are a three tiered module consisting of 
Raf → MEK → MAPKERK conveying signals from 
receptor TKs and G-protein coupled receptors to 
transcription factor in the cell nucleus (Erickson et al., 
1990; Haddad et al., 2003; Ravichandran, 2001; Ray 
and Sturgill, 1987; Tian and Feig, 2001).  
 
Two other signaling cascades are part of the MAP 
kinase system. The stress-induced MAPKp38 mediates 
inflammatory or stress responses to cytokines, such as 
tumor necrosis factor (TNF), genotoxic agents, 
osmotic shock, bacterial lipopolysaccharides, photo-
damage from ultraviolet light, as well as from growth 
factor withdrawal. The other pathway, MAPKJNK/SAPK-
1, transduces several stress signals including 
oxidation/DNA damage along with growth and 
differentiation signals. Both of these pathways are 
activated by a Rac-1 and Cdc-42 signals, which can 
also activate the MAPKERK1/2 system (Vacratsis and 
Gallo, 2000) (Fig. 3).  
 
Figure 3: An overview of the complex network of MAPK signaling pathways and their interactions and 
bifurcations. The sign             denotes inhibition, the solid arrows indicate activation (stimulation); P, 
phosphorylation. 
 
 
The three MAPK pathways do not act in isolation but 
in parallel with limited cross-talk possible. MEKK-3 
directly activates both MKK-6 (activator of MAPKp38) 
and MKK-7 (activator of MAPKJNK), while MKK-4 
(activator of MAPKJNK and MAPKp38) is activated by 
MEKK-2 and MEKK-3. The MAPKJNK pathway 
activates the tumor suppressor gene, p53, which has 
recently been demonstrated to counteract Cdc-42 
(Kumar et al., 1997; Enslen et al., 1998; Herlaar and 
Brown, 1999; Cuenda, 2000; Mielke and Herdegen, 
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2000; Gadea et al., 2002; Hazzalin and Mahadevan, 
2002; Haddad et al., 2003) (Figure 3). (For further 
details on MAPKs signaling pathways, refer to 
Haddad et al., 2003.) 
 
3. Alzheimer’s disease: An overwhelming 
etiological condition or a maneuverable syndrome? 
 
AD is the most common cause of dementia in older 
people (Li et al., 2001; Marx, 2001). Simply put, it’s a 
medical condition that disrupts the way the brain 
works. AD most notably affects the parts of the brain 
that control thought, memory and language 
(Martindale, 2002). Although the risk of getting the 
disease increases with age, it is not a normal part of 
aging (St George-Hyslop, 2000). AD is characterized 
by adult-onset slowly progressive dementia associated 
with diffuse cerebral atrophy on neuro-imaging 
studies. AD is named after Dr. Alois Alzheimer, a 
German psychiatrist (Bardwell, 2006; Wurtman, 
1985).  
 
In 1906, Dr. Alzheimer described changes in the brain 
tissue of a woman who had died of an unusual mental 
illness. He found abnormal deposits (called senile or 
neuritic plaques) and tangled bundles of nerve fibers 
(called NFTs). These plaques and tangles in the brain 
have come to be characteristic brain changes due to 
AD. The diagnosis of AD is based on the histological 
findings of β-amyloid plaques and intra-neuronal 
neurofibrillary tangles. A significant association with 
the e4 allele of apo-lipoprotein E supports the 
diagnosis of AD in patients with dementia and 
increases the risk that asymptomatic individuals will 
eventually develop AD. ApoE genotyping, however, is 
neither fully specific nor sensitive (Bardwell, 2006).  
 
Early and careful evaluation is important because 
many conditions can cause dementia, some of which 
are treatable or ‘reversible.’ Potentially reversible 
conditions include depression, adverse drug reactions, 
metabolic changes, and nutritional deficiencies (St 
George-Hyslop, 2000). A comprehensive patient 
evaluation includes a complete health history, 
physical examination, neurological and mental status 
assessments, and other tests including analysis of 
blood and urine, electrocardiogram, and an imaging 
exam, such as CT or MRI (Anderson et al., 2005). 
While this type of evaluation may provide a diagnosis 
of possible or probable AD, confirmation requires 
examination of brain tissue at autopsy.  
Although no cure for AD is yet available, medical and 
social management of the disease can ease the burdens 
on the patient, and his or her caregiver and family (St 
George-Hyslop, 2000). To date there are four FDA-
approved drugs for the treatment of AD — tacrine 
(Cognex®), donepezil (Aricept®), rivastigmine 
(Exelon®) and galantamine (Reminyl®) — and 
several others in clinical trials. In addition to treating 
the symptoms, advising the patient and his or her 
caregiver to initiate health care directives and 
decisions while the patient still has the capacity to do 
so can ease the burden for the family as the disease 
progresses (Beardsley, 1995; St George-Hyslop, 2000; 
Martindale, 2002).  
 
4. The role of MAPKs in Alzheimer’s: Mechanisms 
and possible therapeutic targets 
 
4.1. Paired helical filaments and Tau 
phosphorylation 
Paired helical filaments (PHFs) are a characteristic 
pathological feature of AD; their principal component 
is the microtubule-associated protein Tau (Fig. 4). The 
Tau in PHFs (PHF-Tau) in AD is hyper-
phosphorylated, but the cellular mechanisms 
responsible for this hyper-phosphorylation are still 
being elucidated (Ganju et al., 1998; St George-
Hyslop, 2000; Zhao et al., 2003). MAPKs are a family 
of Ser/Thr kinases that link cell surface signals to 
changes in enzyme activity and gene expression 
(Shanavas and Papasozomenos, 2000; Haddad, 2002d; 
Haddad et al., 2003).  
 
Moreover, MAPKs have been shown to phosphorylate 
Tau in vitro at Ser/Thr proline sites, thereby 
generating a multiply phosphorylated Tau protein that 
is similar to the hyper-phosphorylated Tau found in 
AD neurofibrillary tangles (NFT) (Dalrymple, 2002; 
Johnson and Bailey, 2003; St George-Hyslop, 2000). 
For instance, fluorescence resonance energy transfer 
(FRET) studies demonstrated a tight intermolecular 
association of activated MAPK with these phospho-
Tau epitopes (Knowles et al., 1999). The 
phosphorylation of normal Tau by MAPKs such as 
MAPKERK induced Tau to acquire biochemical 
properties of AD PHF proteins. In this regards, it was 
shown that a monoclonal antibody to MAP kinases 
could recognize MAPKERK2 (MAPKp42) in normal and 
AD cortex, but MAPKERK2 levels were slightly 
reduced in the AD brain (Trojanowski et al., 1993). 
The hypothesis was that since MAPKERK2 was 
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detected in NFTs and senile plaque neurites in the AD 
hippocampus, MAPKERK2 was positioned to 
phosphorylate normal Tau and could possibly play a 
role in the generation of PHFs in AD.  
 
Figure 4: Schematic diagram depicting the role of kinases and phosphatases acing on Tau protein in 
AD. Tau contains specific phosphorylation sites that are apparently critical for hyper-phosphorylation 
in AD. One class comprises the Ser-Pro and Thr-Pro motifs that determine the reactivity with 
diagnostic antibodies; the other class contains, at least, Ser-262 and has a strong effect on 
microtubule binding. Proline-directed kinases such as MAPKs, GSK-3 and Cdk-5 basically 
phosphorylate Ser-Pro or Thr-Pro motifs, and the Serine-specific kinase phosphorylates Ser-262 in 
the first repeat and the corresponding serines in the other repeats. AD-derived brain extracts usually 
contain a mixture of the aforementioned kinases. The phosphatases calcineurin and PP-2A can 
remove the phosphates from Tau as well as from AD PHFs, thereby acting in an endogenous 
negative feedback mechanism. 
 
 
In contrast, activating MAPK in cultures of primary 
neurons or transfected COS cells expressing Tau 
isoforms did not increase the level of phosphorylation 
for any PHF-Tau epitope investigated (Lovestone et 
al., 1994). However, elevating glycogen synthase 
kinase (GSK)-3 activity in the COS cells by co-
transfection with GSK-3α or GSK-3β decreased the 
electrophoretic mobility of Tau so that it resembled 
that of PHF-Tau, and induced reactivity with PHF-
Tau-selective monoclonal antibodies (Aplin et al., 
1996; Lovestone et al., 1994).  
 
These observations were reinforced by the 
construction of mammalian cell culture systems 
producing high levels of intracellular phosphorylated 
Tau. COS-1 fibroblast-like cells were transiently 
transfected to simultaneously express Tau, MAPK and 
MAPKK, or alternatively to express Tau and GSK-3 
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(Aplin et al., 1996; Baum et al., 1995). B103 neuron-
like cells (which contain MAPK but little Tau or 
GSK-3) were stably transfected to express Tau or Tau 
and GSK-3. In both systems, GSK-3 transfected cells 
contained Tau AT-8/M (defined by AT-8 staining and 
Tau PHF-like mobility), but MAPK-transfected cells 
required phosphatase inhibitors, such as okadaic acid 
(OKA) or calyculin (CAL), to produce Tau AT-8/M. 
In vitro, CAL and OKA inhibited protein phosphatase 
(PP)-1 and PP-2A.  
 
In addition, inducing Tau phosphorylation at the AT-8 
site in MAPK-transfected cells required 2-10 times 
more OKA than CAL, suggesting both PP-1 and PP-
2A helped block the phosphorylation (Baum et al., 
1995; Tanaka et al., 1998). Though levels of Tau AT-
8/M increased in COS-1 cells, the ratio of particulate 
to supernatant Tau levels did not change, and no 
tangles were observed; it was suggested that post-
translational modifications or co-aggregating proteins 
were likely needed to induce PHF (Ghribi et al., 
2003).  
 
4.2. Tau phosphorylation and MAPK inhibition 
Mobility shift, phospho-epitope analysis and direct 
measurement of kinase activity indicated that the 
MEK-1 inhibitor (PD-098059) dose-dependently 
blocked basal and OKA-induced MAPK activation 
(Ekinci and Shea, 1999; Ho et al., 1997; Rapoport and 
Ferreira, 1999, 2000; Schneider et al., 1999). Despite 
a block of MAPK activation by this inhibitor, robust 
Tau hyper-phosphorylation was observed in response 
to OKA. In addition, activation of MAPK by phorbol 
12-myristate 13-acetate (PMA) did not result in Tau 
phosphorylation, indicating that in primary cultures of 
cortical neurons elevated MAPK activity was not 
sufficient to induce Tau hyper-phosphorylation.  
 
Similarly, using immuno-histochemistry, Yamaguchi 
et al. (1996) examined the localization of four types of 
proline-directed kinases in the brains of control rats 
and in the brains of non-demented aged human 
subjects, subjects with AD and those with Down's 
syndrome. The four kinases were: cyclin-dependent 
kinase (cdk)-5, a component of Tau protein kinase 
(TPK)-II, TPK-I/GSK-3β, GSK-3α and MAPKERK2. 
Antiserum for cdk-5 showed the most preferential and 
consistent labeling of intra-neuronal NFT. Antiserum 
for TPK I/GSK-3β also labeled intra-neuronal NFT. 
Double immuno-labeling for TPK I/GSK-3β and Tau-
1 showed that TPK I/GSK-3β was closely associated 
with NFT.  
 
Antiserum for GSK-3α labeled neurons weakly and 
the intensity of labeling did not differ between 
neurons with and without NFT. In addition, antiserum 
for MAPK labeled neurons in superficial cortical 
layers, but NFT appeared in both superficial and deep 
cortical layers (Reynolds et al., 2000; Yamaguchi et 
al., 1996). These findings suggested that cdk-5 and 
TPK I/GSK-3β are the critically important kinases for 
the generation in vivo of hyper-phosphorylated Tau, 
the main component of the paired helical filaments in 
NFT. 
 
In concert with these observations, the novel brain 
protein kinase PK-40 was characterized by its ability 
to phosphorylate Lys-Ser-Pro sites in neuro-filament 
and Tau proteins (Mandelkow et al., 1993). PK-40 is 
recognized as a member of the family of MAPKERK by 
its reactivity with MAPKERK-specific antibodies (PK-
40ERK). Particularly, protein sequence analysis 
suggested that PK-40 is a form of MAPKERK2. Bovine 
Tau or recombinant human Tau proteins can be hyper-
phosphorylated by PK-40ERK to produce the 
electrophoretic mobility shifts and certain 
immunochemical properties characteristic of PHF-Tau 
isolated from AD brain tissue (Trojanowski et al., 
1993).  
 
On the mechanisms related to PK-40ERK, a cAMP-
dependent protein kinase A (PKA)-mediated pathway 
is involved. It was observed that PKA phosphorylates 
Tau to a lesser extent; however, the product is not like 
the hyper-phosphorylated Tau of AD in several 
important respects. Subsequently, it was reported that 
in vitro PK-40ERK further phosphorylates Tau that was 
previously saturated by PKA, provided that the 
concentrations of free un-complexed ATP are low 
(Blanchard et al., 1994; Raghunandan and Ingram, 
1995). Interestingly, the actions of different kinases 
on Tau are not independent, but may depend on the 
order in which they work on Tau; i.e., prior 
phosphorylation by PKA partially inhibits the action 
of PK-40ERK.  
 
Furthermore, a subpopulation of MAPKERK2 species 
in soluble brain fractions can be efficiently 
phosphorylated and activated in cell-free systems, 
simply by adding Mg2+-ATP. Two phospho-isoforms 
of PK-40ERK2 are formed in this process, which have 
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reduced gel mobility, very much like the MAPKERK2 
form obtained in cell culture by stimulation with 
growth factors (Roder et al., 1993; Roder et al., 1995). 
One of these low-mobility forms cannot be inactivated 
with PP-2A or with tyrosine phosphatases; the second 
form can be slowly inactivated by PP-2A. In this case 
two Ser/Thr phosphates are removed at different rates 
during inactivation: One phosphate is very quickly 
removed to result in the formation of a high-mobility 
39-kDa MAPKERK2 species without consequence for 
activity; the other, slowly removed Ser/Thr phosphate 
controls the activity but has no effect on the gel 
mobility of MAPKERK2. These results unequivocally 
showed that forms of MAPKERK2 exist with properties 
different from the previously characterized 
MAPKERK2 (MAPKp42) from stimulated cell cultures. 
The active MAPKERK2 forms produced in the presence 
of Mg2+-ATP alone could provide an explanation for 
the existence of constitutive MAPKERK2-like NFT 
phosphorylation in vivo. Excessive formation of an 
MAPKERK2 species resistant to inactivation by PP-2A 
might be relevant to the persistent pathological Tau 
hyper-phosphorylation in AD. It was subsequently 
postulated that PK-40ERK might play a crucial role in 
the etiology of this disease (Roder et al., 1993; Roder 
et al., 1995).  
 
Furthermore, incubation of rat, human and rhesus 
monkey temporal neo-cortex slices with the 
phosphatase inhibitor OKA induced epitopes of Tau 
similar to those found in PHFs. OKA induced variant 
forms of Tau at 60-68 kDa, which were recognized by 
the monoclonal antibodies Alz-50 (in humans only) 
and 5E2 and two polyclonal anti-peptide antisera, OK-
1 and OK-2 (Garver et al., 1995). The 
phosphorylation-sensitive monoclonal antibody Tau-1 
failed to recognize the slowest mobility forms of Tau 
after okadaic acid treatment. Moreover, FK-520 (1-10 
μM), a potent inhibitor of calcineurin activity, was 
tested in brain slices and found not to alter Tau 
mobility. However, combinations of FK-520 and 
OKA caused Tau mobility shifts similar to those seen 
after OKA treatment; similar results were seen using 
the calcineurin-selective inhibitor cypermethrin 
(Garver et al., 1995). Treatment of human slices with 
OKA decreased both PP-2A and calcineurin activity; 
FK-520 inhibited only PP-2B activity. A proposed 
Tau-directed kinase, 42-kDa MAPKERK2, was 
activated by OKA but not FK-520. Of note, NGF 
activated MAPKERK2, particularly when used in 
combination with OKA; changes in Tau mobility were 
seen when this kinase was activated. Forskolin, in 
addition, antagonized the effects of NGF on both 
MAPKERK2 activity and Tau phosphorylation and 
forskolin alone had little effect on PHF-like Tau 
formation induced by phosphatase inhibitors, 
outlining complex interactions between Tau-directed 
protein kinases and protein phosphatases and 
suggesting potential sites for therapeutic targeting. 
 
4.3. Tau structural analysis and MAPK-related 
protein phosphorylation  
The interactions of Tau protein with microtubules 
could be visualized from two points of view, 
phosphorylation and domain structure (Anderton et 
al., 2001; Angulo et al., 2003; Floyd, 1999; James et 
al., 1996; Jenkins et al., 2000; Mandelkow et al., 
1995; Stein and Johnson, 2003). Tau can be 
phosphorylated at many sites and by several kinases, 
notably by proline-directed kinases (MAPK, GSK-3, 
cdk-5), which generate Alzheimer-like antibody 
epitopes. Other kinases phosphorylate Ser 262, a site 
that has a particularly pronounced influence on the 
affinity of Tau for microtubules (Fig. 4). All of these 
sites can be cleared by phosphatases PP-2A and CAL. 
The site Ser-262 lies within the repeat domain of Tau. 
However, when probing the domains of Tau for their 
effects on microtubule binding, nucleation, assembly, 
or bundling, the repeat domain has only a weak 
influence. Whereas the repeat domain of Tau binds to 
microtubules with low affinity, repeat-less Tau binds 
strongly yet unproductively in terms of microtubule 
assembly.  
 
Productive binding of Tau to microtubules depends on 
the combination of repeats with the flanking regions, 
as if the flanking regions acted as ‘jaws’ for the proper 
positioning of Tau on the microtubule surface. 
Analysis of phosphorylation of Tau is often performed 
using phosphorylation-sensitive monoclonal 
antibodies thought to report the presence or absence of 
one or two specific phosphorylations (cognate sites). 
Using several such antibodies, it was found that a 
much more complicated relationship existed between 
phosphorylation at specific sites, as monitored by two-
dimensional phospho-peptide mapping, and antibody 
recognition of these sites (Roder et al., 1997). 
Multiple phosphorylation of Tau in several stages by 
PK-40, for instance, suggested that phosphorylation at 
cognate sites is sometimes necessary, but not 
sufficient, to induce a change of antibody reactivity 
and in some cases is not even necessary in the 
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background of multiple phosphorylation at other sites. 
No single phosphorylation site was found to be 
responsible for any level of gel mobility shift 
associated with phosphorylation. Moreover, Tau 
acquired its maximal gel mobility retardation and final 
immunochemical profile at sub-stoichiometric 
phosphorylation of most sites. This suggested that 
many alternate phosphorylation patterns could 
produce the same conformational and 
immunochemical presentation on SDS-PAGE. 
Although PK-40ERK2 prefers some phosphorylation 
sites, most notably Ser-235, followed by Ser-199 or 
Ser-202 and Thr-205, the phosphorylation of multiple 
Ser/Thr-Pro sites is not highly sequential (Fig. 4). Ser-
396 is one of the least preferred sites and seems to 
require prior phosphorylation at Ser-404.  
 
Moreover, MAPK immunoreactivity and in situ 
hybridization patterns of the two major genes that 
comprise MAPK activity, MAPKERK1 and MAPKERK2, 
were reported in the human hippocampal formation 
(Hyman et al., 1994). The goal was to determine 
whether the pattern of MAPKERK expression was 
consistent with the hypothesis that MAPKs directly 
contribute to NFT formation. MAPKERK1 mRNA was 
detected in small amounts and confined primarily to 
dentate gyrus granule cells (Hyman et al., 1994). 
MAPKERK2 mRNA, by contrast, gave a much stronger 
hybridization signal and was present in dentate gyrus 
granule cells and pyramidal cells throughout all 
hippocampal sub-fields and adjacent temporal neo-
cortex. Quantitative measures of MAPKERK2 mRNA 
revealed that neuro-filament bearing neurons 
contained approximately 15% less MAPKERK2 mRNA 
than nearest normal neighbors (Hyman et al., 1994). 
NFT-bearing neurons contained approximately 25% 
less poly-A mRNA, suggesting a relative preservation 
of MAPKERK2 mRNA even in metabolically 
compromised cells.  
 
MAPK immunoreactivity (which represented both 
MAPKERK1 and MAPKERK2) was reported in neuronal 
soma, dendrites, axons and in reactive astrocytes 
(Hyman et al., 1994). In AD, neurons that contain 
NFTs are also MAPK immunoreactive, but neurons 
that contain the highest amounts of MAPK 
immunoreactivity are not necessarily vulnerable for 
NFTs. MAPK immunoreactivity was present in the 
same neurons as NFTs and in the same subcellular 
compartments as Tau, supporting a role for MAPKs in 
Tau phosphorylation in AD. However, the presence of 
MAPKERK immunoreactivity was not sufficient to 
predispose neurons to NFT formation (Korneyev, 
1998). 
 
4.4. Tau/β-APP-mediated phosphorylation 
mechanisms and MAPK regulation  
Biological effects related to cell growth, as well as a 
role in the pathogenesis of AD, have been ascribed to 
the β-amyloid precursor protein (β-APP). The 
aberrant expression or processing of β-APP is the only 
known genetic basis for presenile familial AD, and the 
molecular connection between β-APP and Tau has 
always been perplexing (Grant et al., 1999; Jones et 
al., 1999; Wirths et al., 2006). Transgenic 
experiments, for instance, have revealed that long-
term memory is dependent on cAMP-response 
element binding protein, CREB (Sato et al., 1997). 
CREB phosphorylation at Ser-133 is essential for its 
transcriptional activity. In this respect, it was 
demonstrated that β-APP induced CREB 
phosphorylation at Ser-133 in rat pheochromocytoma 
PC-12 cells. β-APP, furthermore, induced the 
phosphorylation of MAPKERK1 and MAPKERK2 at Tyr-
204, and PD-98059, a MEK1 inhibitor, inhibited β-
APP-induced CREB phosphorylation at serine-133 
(Sato et al., 1997). It was concluded that elevated β-
APP level induces CREB phosphorylation at Ser-133 
via MAPKERK1/2-dependent pathway.  
 
In addition, it was reported that the secreted form of 
β-APP potently stimulates MAPKs. For instance, brief 
exposure of PC-12 pheochromocytoma cells to β-APP 
secreted by transfected Chinese hamster ovary cells 
stimulated the 43-kDa form of MAPK (Greenberg et 
al., 1994). Induction of a dominant inhibitory form of 
Ras in a PC-12-derived cell line prevented the 
stimulation of MAPK by secreted β-APP, 
demonstrating the dependence of the effect upon p21-
Ras. Moreover, it was found that enhancement in Tau 
phosphorylation was associated with the β-APP-
induced MAPK stimulation (Greenberg et al., 1994). 
In the Ras dominant inhibitory cell line, β-APP failed 
to enhance phosphorylation of Tau, thereby providing 
a link between secreted β-APP and the 
phosphorylation state of Tau. Furthermore, β-APP has 
been shown to serve as a G0-coupled receptor in cell-
free systems (Okamoto et al., 1995). It was shown that 
stimulation of β-APP by anti-APP antibody as well as 
by a mutation found in familial AD resulted in the 
activation of a specific set of MAPK in multiple 
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vertebrate cells (Murayama et al., 1996), thereby 
concluding that β-APP might act as a cell surface 
receptor of biological relevance that turns on specific 
Ser/Thr kinases, and suggested that the signaling 
function of β-APP is a potential target of familial AD 
mutations (Oakley et al., 2006). 
 
On the mechanisms reported, β-APP, which 
accumulates extracellularly in AD brain, induces Ca2+ 
influx in culture via the L-gated voltage-sensitive Ca2+ 
channel. Since this channel is normally activated by 
PKA-mediated phosphorylation, kinase activities 
recruited following β-APP treatment of cortical 
neurons and SH-SY-5Y neuroblastoma were 
examined. β-APP increased channel phosphorylation; 
this increase was unaffected by the PKA inhibitor, 
H89, but was reduced by PD-98059 (Abe and Saito, 
2000; Ekinci et al., 1999; Guise et al., 2001).  
 
Pharmacological and antisense oligonucleotide-
mediated reduction of MAPK activity also reduced β-
APP-induced accumulation of Ca2+, reactive oxygen 
species (ROS), phospho-Tau immunoreactivity and 
apoptosis, indicating that MAPK mediates multiple 
aspects of β-APP-induced neuro-toxicity and 
suggesting that Ca2+ influx initiates neuro-
degeneration in AD (Zhang and Jope, 1999). In 
addition, β-APP increased MAPK-mediated 
phosphorylation of membrane-associated proteins and 
reduced phosphorylation of cytosolic proteins without 
increasing overall MAPK activity (Ekinci et al., 
1999). Increasing MAPK activity with EGF did not 
increase channel phosphorylation, to indicate that 
redirection, rather than increased activation, of MAPK 
activity mediates β-APP-induced neuro-toxicity 
(Canet-Aviles et al., 2002).  
 
Another mechanism known involves 
phosphatidylinositol 3-kinase (PI3-K) (Shaw et al., 
2001). Because of the physiological role of PI3-K in 
the translocation of glucose transporter-containing 
vesicles, it was speculated that PI3-K involvement in 
β-APP metabolism might act at the level of vesicular 
trafficking (Solano et al., 2000). In accord with the 
aforementioned observations, exposure of primary rat 
microglia and human THP-1 monocytes to β-APP 
resulted in the tyrosine kinase-dependent activation of 
two parallel signal transduction cascades involving 
members of the MAPK superfamily. β-APP 
stimulated the rapid, transient activation of 
MAPKERK1/2 in microglia and only MAPKERK2 in 
THP-1 monocytes (McDonald et al., 1998).  
 
A second superfamily member, MAPKp38, was also 
activated with similar kinetics. Scavenger receptor and 
receptor for advanced glycated end products (RAGE) 
ligands failed to activate MAPKERK and MAPKp38 in 
the absence of significant increases in protein tyrosine 
phosphorylation, demonstrating that scavenger 
receptors and RAGE are not linked to these pathways 
(McDonald et al., 1998; Sun et al., 2003). Importantly, 
MAPKJNK SAPKs were not significantly activated in 
response to β-APP. Moreover, exposure of microglia 
and THP-1 monocytes to β-APP resulted in the 
activation of RSK-1 and RSK-2 and phosphorylation 
of CREB at Ser-133, providing a mechanism for β-
APP -induced changes in gene expression (McDonald 
et al., 1998).  
 
In reinforcement of these reports, Shin et al. (1999) 
investigated the role of presenilin-1 (PS-1) in the 
secretion of α-secretase derived sAPP-α and 
associated intracellular signaling pathways. Human 
embryonic kidney (HEK) 293 cells, in this respect, 
were transfected with exon-9 deletion (ΔE9) mutant 
PS-1 cDNA in an ecdyson-inducible system. sAPP-α 
secretion was lower in the mutant PS-1 expressing 
cells compared with non-expressing cells (Shin et al., 
1999). When activated by PDBu, secretion of sAPP-α 
and the level of phosphorylated MAPK were 
enhanced in ΔE9 PS-1 un-induced cells, but not in the 
mutant PS-1 induced cells. PD-98059, in addition, 
blocked PDBu induced sAPP-α secretion from ΔE9 
PS-1 un-induced cells, but had no effect on the mutant 
PS-1 induced cells, indicating that PS-1 mediates 
PDBu-induced sAPP-α secretion and MAPK 
activation.  
 
In contrast to the neutral role of MAPKJNK and 
MAPKp38 in AD, using nano-electrospray mass 
spectrometry, an extensive phosphorylation in vitro by 
several candidate Tau kinases, namely, MAPKJNK, 
MAPKp38, MAPKERK2 and GSK-3β was observed 
(between 10 and 15 sites were identified for each 
kinase). The three MAPKs phosphorylated Ser-202 
and Thr-205 but not detectably Ser-199, whereas 
conversely GSK-3β phosphorylated Ser-199 but not 
detectably Ser-202 or Thr-205 (Otth et al., 2003; 
Reynolds et al., 2000; Troy et al., 2001). In addition, 
phosphorylated Ser-404 was found with all of these 
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kinases except MAPKJNK. To recapitulate, the MAP 
kinases may not be strictly proline specific: MAPKp38 
phosphorylated the non-proline sites Ser-185, Thr-
245, Ser-305 and Ser-356, whereas MAPKERK2 was 
the strictest. Furthermore, all of the sites detected 
except Thr-245 and Ser-305 are known or suspected 
phosphorylation sites in paired helical filament-Tau 
extracted from AD brains, suggesting that the three 
MAPKs are importantly all strong candidates as Tau 
kinases that may be involved in the pathogenic hyper-
phosphorylation of Tau in AD (Reynolds et al., 2000; 
Zhu et al., 2000).  
 
In addition, Thr-668 within the carboxy-terminus of 
the AD β-APP is a known in vivo phosphorylation 
site. Phosphorylation of β-APP/Thr-668 is believed to 
regulate β-APP function and metabolism (Standen et 
al., 2001). Thr-668 precedes a proline, which suggests 
that it is targeted for phosphorylation by proline-
directed kinase(s). The ability of four major 
neuronally active proline-directed kinases, cdk-5, 
GSK-3β, MAPKERK2 and MAPKJNK1 to phosphorylate 
β-APP/Thr-668 indicated a robust phosphorylation of 
this site both in vitro and in vivo (Figure 4) (Matsuda 
et al., 2001; Troy et al., 2001).  
 
Another interesting mechanism reported for the action 
of β-APP in AD indicated a major role for glutamate, 
the principal excitatory neurotransmitter in the 
mammalian brain. Several lines of evidence suggested 
that glutamatergic hypo-activity exists in the AD 
brain, where it may contribute to both brain amyloid 
burden and cognitive dysfunction (Mills and Reiner, 
1999). Although metabotropic glutamate receptors 
(Haddad, 2005) have been shown to alter cleavage of 
β-APP, little attention has been paid to the role of 
NMDA receptors in this process. It was reported that 
the activation of NMDA receptors in transiently 
transfected human embryonic kidney 293 cells 
increased the production of sAPP (Mills and Reiner, 
1999).  
 
Moreover, using both pharmacological and gene 
transfer techniques, it was shown that this effect was 
largely due to activation of the MAPK, specifically 
MAPKERK. These observations further our 
understanding of the pathways that regulate APP 
cleavage and buttress the notion that regulation of β-
APP is critically dependent upon MAPKs (Bi et al., 
2000).  
 
Conversely, β-APP has been reported to induce the 
phosphorylation of MAPKs. For instance, using acute 
and organotypic hippocampal slice preparations, 
Dineley et al. (2001) demonstrated that β-APP peptide 
1-42 (β-APP42) couples to the MAPK cascade via α7 
nicotinic acetylcholine receptors (nAChR). In vivo 
elevation of β-APP, such as that exhibited in animal 
models for AD, leads to the upregulation of α7-
nAChR protein. This upregulation occurred 
concomitantly with the down-regulation of 
MAPKERK2 in hippocampi of aged animals (Dineley et 
al., 2001).  
 
The phosphorylation state of a transcriptional 
mediator of long-term potentiation and a downstream 
target of the MAPKERK cascade, CREB protein, were 
affected also, supporting the model that derangement 
of hippocampus signal transduction cascades in AD 
arises as a consequence of increased β-APP burden 
and chronic activation of MAPKERK in an α7-nAChR-
dependent manner that eventually leads to the down-
regulation of MAPKERK2 and decreased 
phosphorylation of CREB protein. Potential pathways 
involving cell death-related cofactors and AD are 
schematized in Fig. 5. 
 
4.5. Redox/oxidative mechanisms and MAPK-
mediated Tau phosphorylation 
Oxidative stress play a major role on the pathogenesis 
of AD (Chen et al., 2003; de la Monte et al., 2000; 
Floyd, 1999; Tamagno et al., 2003). For example, 
increased expression of heme oxygenase-1 (HO-1) is 
a common feature in a number of neuro-degenerative 
diseases, including AD (Floyd, 1999; Haddad, 2002d; 
Haddad, 2003; Haddad, 2006; Haddad and Land, 
2000a; Haddad and Land, 2000b; Haddad et al., 2000; 
Takeda et al., 2000; Zhang and Jope, 1999). 
Interestingly, the spatial distribution of HO-1 
expression in diseased brain is essentially identical to 
that of pathological expression of Tau.  
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Figure 5: A diagrammatic scheme showing potential caspase/apoptosis pathways in the 
development of AD due to chronic injury caused by the excessive deposition of β-APP and NFT. AD, 
Alzheimer’s; APP, Amyloid precursor protein; ER, Endoplasmic reticulum; NFT, Neurofibrillary tangle; 
PHF, Paired helical formation. 
 
 
The relationship between HO-1 and Tau was 
explored, using neuroblastoma cells stably transfected 
with sense and antisense HO-1 constructs, as well as 
with the vector alone. In transfected cells over-
expressing HO-1, the activity of heme oxygenase was 
increased, and conversely, the level of Tau protein 
was dramatically decreased, when compared with 
antisense HO-1 or CEP transfected cells (Haddad, 
2002c; Haddad, 2002d; Takeda et al., 2000). The 
suppression of Tau protein expression was almost 
completely reversed by zinc-deuteroporphyrin, a 
specific inhibitor of HO activity. The activated forms 
of MAPKERK were also decreased in cells over-
expressing HO-1, although no changes in the 
expression of total MAPKERK1/2 proteins were 
observed (Takeda et al., 2000).  
 
These data are in agreement with the finding that the 
expression of Tau is regulated through signal cascades 
including the MAPKERK, whose activities are 
modulated by oxidative stresses (Fig. 6). The 
expression of Tau and HO-1, then, may be regulated 
by oxidative stresses (Haddad, 2002b; Haddad, 2002c) 
in a coordinated manner and play a pivotal role in the 
cytoprotection of neuronal cells (Pei et al., 2003).  
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Figure 6: The role of selective MAPKs, mitogenic stimuli and oxidative stress in the development and 
evolution of AD. 
 
 
4.6. Inflammatory mediators and MAPK-mediated 
Tau phosphorylation 
Inflammatory mediators (Haddad, 2002d; Haddad, 
2002e; Haddad and Harb, 2005a; Haddad and Harb, 
2005b) have been implicated in the pathophysiology 
of neuro-degenerative diseases, including AD (Paris et 
al., 2003; Xia and Hyman, 2002). For instance, the 
chemokine receptor CXCR3 and its ligand, IP-10, 
were detected in AD brains (Xia et al., 2000). CXCR3 
was detected constitutively on neurons and neuronal 
processes in various cortical and sub-cortical regions; 
IP-10 was observed in a subpopulation of astrocytes in 
normal brain and was markedly elevated in astrocytes 
in AD brains. Many IP-10+ astrocytes were also 
associated with senile plaques and had an apparently 
coordinated upregulation of MIP-1β (Xia et al., 2000). 
Moreover, it was shown that CXCR3 ligands, IP-10 
and Mig, were able to activate MAPKERK1/2 pathway 
in mouse cortical neurons, suggesting a novel 
mechanism of neuronal-glial interaction.  
 
Similarly, one of the CXCR2 ligands GRO-α/KC can 
be a potent trigger for the MAPKERK1/2 and PI-3 
kinase pathways, as well as Tau hyper-
phosphorylation in the mouse primary cortical 
neurons (Xia and Hyman, 2002). GRO-α 
immunoreactivity can be also detected in a 
subpopulation of neurons in normal and AD. 
Therefore, the CXCR2-ligand pair may have a potent 
pathophysiological role in neuro-degenerative 
diseases.  
 
In concert with this, reactive microglia have been 
suggested to play a role in AD process, and previous 
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studies have shown that expression of CD45, a 
membrane-bound protein-tyrosine phosphatase (PTP), 
is elevated in microglia in AD brains (Tan et al., 
2000). To investigate the possible role of CD45 in 
microglial responsiveness to β-APP, primary cultured 
microglia were co-treated with a tyrosine phosphatase 
inhibitor [potassium bisperoxo (1,10-phenanthroline) 
oxovanadate (phen), 5 micrometer] and freshly 
solubilized β-APP peptides (1000 nm). Data showed 
synergistic induction of microglial activation as 
evidenced by TNF-α production and nitric oxide (NO) 
release, both of which were dependent on the 
activation of MAPKERK1/2. Furthermore, co-treatment 
with phen and β-APP peptides resulted in microglia-
induced neuronal cell injury (Fig. 5). Stimulation of 
microglial CD45 by anti-CD45 antibody markedly 
inhibited these effects via inhibition of MAPKERK1/2, 
suggesting that CD45 is a negative regulator of 
microglial activation (Tan et al., 2000). Accordingly, 
primary cultured microglia from CD45-deficient mice 
demonstrated hyper-responsiveness to β-APP, as 
evidenced by TNF-α release, NO production and 
neuronal injury after stimulation with β-APP peptides.  
 
As a validation of these findings in vivo, brains from a 
transgenic mouse model of AD [transgenic Swedish 
APP-over-expressing (Tg APP(Sw)) mice] deficient 
for CD45 demonstrated markedly increased 
production of TNF-α, compared with Tg APP(Sw) 
mice (Chong et al. 2001; Smits et al., 2001; Tan et al., 
2000; Tomidokoro et al., 2001; Del Villar and Miller, 
2004). Taken together, these results suggested that 
therapeutic agents that stimulate the CD45/PTP 
signaling pathway might be effective in suppressing 
microglial activation associated with AD.  
 
Moreover, a similar mechanism has been proposed for 
IL-1. For instance, activated MAPKp38 and IL-1 have 
both been implicated in the hyper-phosphorylation of 
Tau (Sheng et al., 2001). This, together with findings 
showing that IL-1 activates MAPKp38 in vitro and is 
markedly over-expressed in AD brain, suggested a 
role for IL-1-induced MAPKp38 activation in the 
genesis of NFT in AD. Frequent co-localization of 
hyper-phosphorylated Tau protein (AT8 antibody) and 
activated MAPKp38 in neurons and in dystrophic 
neurites in AD and frequent association of these 
structures with activated microglia over-expressing 
IL-1 were reported (Sheng et al., 2001). Tissue levels 
of IL-1 mRNA as well as of both phosphorylated and 
non-phosphorylated isoforms of Tau were elevated in 
those brains.  
 
Furthermore, significant correlations were found 
between the numbers of AT8- and MAPKp38-
immunoreactive neurons, and between the numbers of 
activated microglia over-expressing IL-1 and the 
numbers of both AT8- and MAPKp38-immunoreactive 
neurons. In addition, rats bearing IL-1-impregnated 
pellets showed a six- to seven-fold increase in the 
levels of MAPKp38 mRNA, compared with rats with 
vehicle-only pellets (Sheng et al., 2001). These results 
suggested that microglial activation and IL-1 
overexpression are part of a feedback cascade in 
which MAPKp38 overexpression and activation leads 
to Tau hyper-phosphorylation and NFT pathology in 
AD (Atzori et al., 2001; Daniels et al., 2001; Ferrer et 
al., 2001; Williamson et al., 2002; Hoozemans et al., 
2004). More recently, IL-6 was also reported to 
induce Alzheimer-type phosphorylation of Tau 
protein by deregulating the cdk5/p35 pathway 
(Quintanilla et al., 2004). 
 
5. Summary, conclusions and future prospects 
There are multiple lines of evidence showing that 
oxidative stress (Haddad, 2004a; Haddad, 2004b) and 
aberrant mitogenic signaling (Zhu et al., 2002) play an 
important role in the pathogenesis of AD (Churcher, 
2006; Haddad and Land, 2000a; Haddad and Land, 
2000b; Haddad et al., 2000; Zhu et al., 2001a; 2001b) 
(Fig. 6). However, the chronological relationship 
between these and other events associated with 
disease pathogenesis is not strictly elucidated. Given 
the crucial role that MAPK pathways play in 
mitogenic signaling (MAPKERK) and cellular stress 
signaling (MAPKJNK/SAPK and MAPKp38), the 
chronological and spatial relationship between 
activated MAPKs during disease progression is 
warranted (Savage et al., 2002; Taru et al., 2002). 
While all three kinases are activated in the same 
susceptible neurons in mild and severe cases, in non-
demented cases with limited pathology, both 
MAPKERK and MAPKJNK are activated but MAPKp38 
is not (Ferrer et al., 2005). However, in non-demented 
cases lacking any sign of pathology, either MAPKERK 
alone or MAPKJNK alone can be activated, indicating 
that MAPK pathways are differentially activated 
during the course of AD and, by inference, suggesting 
that both oxidative stress/inflammatory and 
abnormalities in mitotic signaling can independently 
serve to initiate, but both are necessary to propagate, 
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disease pathogenesis (Daniels et al., 2001; Koistinaho 
et al., 2002).  
 
The complex molecular interactions between MAPKs 
and proteins (plagues) associated with the evolution of 
AD form a cornerstone in the knowledge of a 
burgeoning field of neurodegenerative, inflammatory 
diseases and ageing (Ho et al., 2005). MAPKs, 
therefore, may constitute a neurogenetic, therapeutic 
target for the diagnosis of a preventative medical 
strategy for early detection, and possible treatment, of 
Alzheimer’s. 
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